These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16507327)

  • 1. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
    Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
    Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
    Vansteenkiste J; Canon JL; Riska H; Pirker R; Peterson P; John W; Mali P; Lahn M
    Invest New Drugs; 2005 Jun; 23(3):263-9. PubMed ID: 15868384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
    Paz-Ares L; Douillard JY; Koralewski P; Manegold C; Smit EF; Reyes JM; Chang GC; John WJ; Peterson PM; Obasaju CK; Lahn M; Gandara DR
    J Clin Oncol; 2006 Mar; 24(9):1428-34. PubMed ID: 16549837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
    Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
    J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
    Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.
    Shirai T; Hirose T; Noda M; Ando K; Ishida H; Hosaka T; Ozawa T; Okuda K; Ohnishi T; Ohmori T; Horichi N; Adachi M
    Lung Cancer; 2006 May; 52(2):181-7. PubMed ID: 16563558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Ritch P; Figueroa JA; Otterson GA; Belt R; Dow E; George S; Leonardo J; McCachren S; Miller GL; Modiano M; Valdivieso M; Geary R; Oliver JW; Holmlund J
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6086-93. PubMed ID: 15447994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
    Brodowicz T; Krzakowski M; Zwitter M; Tzekova V; Ramlau R; Ghilezan N; Ciuleanu T; Cucevic B; Gyurkovits K; Ulsperger E; Jassem J; Grgic M; Saip P; Szilasi M; Wiltschke C; Wagnerova M; Oskina N; Soldatenkova V; Zielinski C; Wenczl M;
    Lung Cancer; 2006 May; 52(2):155-63. PubMed ID: 16569462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
    J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
    Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
    J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
    Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
    Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
    Sovak MA; Lutzker S; Zheng L; Guensch L; Joyce M; Schwartz S; Wu Y; Aisner J
    Lung Cancer; 2006 Aug; 53(2):177-81. PubMed ID: 16790293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
    Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
    Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
    Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
    J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.